Feb 01, 2018

Silicon Republic interviews patientMpower’s Eamonn Costello

Silicon Republic recently spoke with Eamonn Costello of patientMpower where he discusses the potential to deliver technology that could change the face of healthcare.

Eamonn Costello is the CEO of patientMpower. Prior to co-founding PatientMpower in 2014, Costello held the role of director at MEG Support Tools, and was also COO at XSellco. Based at The Digital Hub in Dublin 8, PatientMpower is contributing to the medtech revolution, aiming to create positive outcomes for those with kidney and lung disease.

 

Last week (24 January), it took part in the IPF Catalyst Challenge in Chicago and was named joint winner, splitting the $1m prize fund with Advanced Interactive Response Systems and Owlstone Medical.

 

Describe your role and what you do.

As CEO, my job is to provide the strategic direction for PatientMpower. We have a strong engineering, scientific and medical team, and I work to ensure they have the resources to ensure we execute on our plans. A lot of my time is spent establishing relationships with healthcare providers in our therapeutic areas (lung disease, kidney disease) and talking to users of our solutions (patients and healthcare workers).

How do you prioritise and organise your working life?

With two kids under two, I’ve got more disciplined with my time in the last few years. Unless travelling, I have my week structured, with time set in the calendar to focus on different areas of the business, while setting time aside to be flexible for things that pop up. All of my planning is done through Google Calendar and Google Notes. About one week in six (currently), I’m in the US – generally east coast and mid-west – meeting customers and partners, building relationships.

What are the biggest challenges facing your business and how are you tackling them?

Technology has the potential to transform healthcare but generating huge volumes of data with no insights would be counterproductive. We are developing digital therapeutics where we are generating insights into what’s happening with a patient, and the healthcare provider is not overburdened with data.

We are working with the FDA to ensure our solutions comply with US regulations, and also work to ensure we comply with various data regulations (HIPAA, GDPR). We are also performing clinical trials to ensure we build the evidence that our solutions are having an impact on people’s lives, and this evidence will be critical for our reimbursement case with health providers.

This article originally appeared on Siliconrepublic.com and you can read the full article at: https://www.siliconrepublic.com/innovation/patientmpower-eamonn-costello-medtech